Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Jonathan Moss

TitleEmeritus/Emerita, Professor
InstitutionUniversity of Chicago
DepartmentAnesthesiology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Moss J. Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 01; 130(1):142-148. PMID: 30277930.
      View in: PubMed
    2. Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 11; 27(11):2032-2038. PMID: 27573565.
      View in: PubMed
    3. Wang CZ, Moss J, Yuan CS. Commonly Used Dietary Supplements on Coagulation Function during Surgery. Medicines (Basel). 2015 Sep; 2(3):157-185. PMID: 26949700.
      View in: PubMed
    4. Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15; 121(16):2681-8. PMID: 26043235.
      View in: PubMed
    5. Moss J, Paterson C. Methylnaltrexone (Relistor®) does not impact opioid-mediated analgesia at therapeutic doses. Pain. 2014 Dec; 155(12):2722. PMID: 25149144.
      View in: PubMed
    6. Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577. PMID: 24662916.
      View in: PubMed
    7. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67. PMID: 22343475.
      View in: PubMed
    8. Lennon FE, Moss J, Singleton PA. The µ-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012 Apr; 116(4):940-5. PMID: 22357347.
      View in: PubMed
    9. Babrowski T, Holbrook C, Moss J, Gottlieb L, Valuckaite V, Zaborin A, Poroyko V, Liu DC, Zaborina O, Alverdy JC. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann Surg. 2012 Feb; 255(2):386-93. PMID: 21989372.
      View in: PubMed
    10. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67. PMID: 21156980.
      View in: PubMed
    11. Singleton PA, Moss J. Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010 Aug; 6(8):1237-42. PMID: 20799870.
      View in: PubMed
    12. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010 Feb 19; 2(1):5. PMID: 20298531.
      View in: PubMed
    13. Ladanyi A, Temkin SM, Moss J. Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user. Int J Gynecol Cancer. 2010 Feb; 20(2):308-10. PMID: 20134275.
      View in: PubMed
    14. Woo M, O'Connor M, Yuan CS, Moss J. Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg. 2008 Dec; 107(6):1965-7. PMID: 19020145.
      View in: PubMed
    15. Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc. 2008 Oct; 83(10):1116-30. PMID: 18828971.
      View in: PubMed
    16. Singleton PA, Garcia JG, Moss J. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. . 2008 Jun; 7(6):1669-79. PMID: 18566238.
      View in: PubMed
    17. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007 Aug; 37(2):222-31. PMID: 17395891.
      View in: PubMed
    18. Wicks SM, Tong R, Wang CZ, O'Connor M, Karrison T, Li S, Moss J, Yuan CS. Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14. PMID: 17597499.
      View in: PubMed
    19. Yuan CS, Doshan H, Charney MR, O'connor M, Karrison T, Maleckar SA, Israel RJ, Moss J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46. PMID: 15831777.
      View in: PubMed
    20. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004 Jul 06; 141(1):23-7. PMID: 15238367.
      View in: PubMed
    Moss's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _